Serum levels and significance of soluble B-cell maturation antigen in childhood-onset systemic lupus erythematosus with renal involvement
暂无分享,去创建一个
[1] M. Talebi,et al. B-cell maturation antigen targeting strategies in multiple myeloma treatment, advantages and disadvantages , 2022, Journal of translational medicine.
[2] Jing Shi,et al. Study on the Relationship Between the Expression of B Cell Mature Antigen and the Classification, Stage, and Prognostic Factors of Multiple Myeloma , 2021, Frontiers in Immunology.
[3] Hyun-Dong Chang,et al. Keeping up with the stress of antibody production: BAFF and APRIL maintain memory plasma cells. , 2021, Current opinion in immunology.
[4] N. Xu,et al. Baseline and Changes in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Patients with Relapsed/Refractory Multiple Myeloma Starting New Therapy , 2021, Targeted Oncology.
[5] T. Spektor,et al. Baseline serum B‐cell maturation antigen levels predict time to disease progression for patients with smoldering multiple myeloma , 2021, European journal of haematology.
[6] Yoshiya Tanaka,et al. Systemic Lupus Erythematosus: Targeted Literature Review of the Epidemiology, Current Treatment, and Disease Burden in the Asia Pacific Region , 2020, Arthritis care & research.
[7] W. Alturaiki. The roles of B cell activation factor (BAFF) and a proliferation-inducing ligand (APRIL) in allergic asthma. , 2020, Immunology letters.
[8] T. Spektor,et al. Normalization of serum B‐cell maturation antigen levels predicts overall survival among multiple myeloma patients starting treatment , 2020, British journal of haematology.
[9] E. Frangou,et al. Update on the cellular and molecular aspects of lupus nephritis. , 2020, Clinical immunology.
[10] T. Spektor,et al. Estimating a normal reference range for serum B‐cell maturation antigen levels for multiple myeloma patients , 2020, British journal of haematology.
[11] J. Muñóz-Valle,et al. Analysis of the receptor BCMA as a biomarker in systemic lupus erythematosus patients , 2020, Scientific Reports.
[12] H. Anders,et al. Lupus nephritis , 2009, Nature Reviews Disease Primers.
[13] C. Cunningham-Rundles,et al. Serum B cell maturation antigen (BCMA) levels differentiate primary antibody deficiencies. , 2020, The journal of allergy and clinical immunology. In practice.
[14] T. Chan,et al. B Cell Abnormalities in Systemic Lupus Erythematosus and Lupus Nephritis—Role in Pathogenesis and Effect of Immunosuppressive Treatments , 2019, International journal of molecular sciences.
[15] B. Wood,et al. γ-secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. , 2019, Blood.
[16] N. Xu,et al. Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells. , 2019, Leukemia research.
[17] F. Mackay,et al. Analysis of serum B cell‐activating factor from the tumor necrosis factor family (BAFF) and its soluble receptors in systemic lupus erythematosus , 2019, Clinical & translational immunology.
[18] E. Meinl,et al. Shedding of BAFF/APRIL Receptors Controls B Cells. , 2018, Trends in immunology.
[19] H. Brunner,et al. Childhood-Onset Systemic Lupus Erythematosus: A Review and Update. , 2018, The Journal of pediatrics.
[20] Giovanna Flores-Mendoza,et al. Mechanisms of Tissue Injury in Lupus Nephritis. , 2018, Trends in molecular medicine.
[21] Saurabh Patil,et al. The Role of B-Cell Maturation Antigen in the Biology and Management of, and as a Potential Therapeutic Target in, Multiple Myeloma , 2018, Targeted Oncology.
[22] R. Hohlfeld,et al. Human Plasmacytoid Dendritic Cells Display and Shed B Cell Maturation Antigen upon TLR Engagement , 2017, The Journal of Immunology.
[23] T. Spektor,et al. Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients , 2016, Haematologica.
[24] G. Valesini,et al. Assessment of disease activity in Systemic Lupus Erythematosus: Lights and shadows. , 2015, Autoimmunity reviews.
[25] T. Olsson,et al. γ-secretase directly sheds the survival receptor BCMA from plasma cells , 2015, Nature Communications.
[26] W. Stohl. Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus , 2014, Expert opinion on therapeutic targets.
[27] J. Liese,et al. Reference values for B cell subpopulations from infancy to adulthood , 2010, Clinical and experimental immunology.
[28] Yen-Ming Hsu,et al. Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA. , 2005, Biochemistry.
[29] Lee Hebert,et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. , 2004, Journal of the American Society of Nephrology : JASN.
[30] R. Bram,et al. BCMA Is Essential for the Survival of Long-lived Bone Marrow Plasma Cells , 2004, The Journal of experimental medicine.
[31] M. Hochberg,et al. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. , 1997, Arthritis and rheumatism.
[32] J. Klippel,et al. Prognostic factors in lupus nephritis. Contribution of renal histologic data. , 1983, The American journal of medicine.